Graphite Bio, Inc. (GRPH): Price and Financial Metrics

Graphite Bio, Inc. (GRPH): $1.94

0.01 (+0.52%)

POWR Rating

Component Grades













Add GRPH to Watchlist
Sign Up

Industry: Biotech



in industry

GRPH Stock Price Chart Interactive Chart >

Price chart for GRPH

GRPH Price/Volume Stats

Current price $1.94 52-week high $11.30
Prev. close $1.93 52-week low $1.59
Day low $1.91 Volume 119,084
Day high $1.98 Avg. volume 483,317
50-day MA $2.87 Dividend yield N/A
200-day MA $3.15 Market Cap 112.81M

Graphite Bio, Inc. (GRPH) Company Bio

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

GRPH Latest News Stream

Event/Time News Detail
Loading, please wait...

GRPH Latest Social Stream

Loading social stream, please wait...

View Full GRPH Social Stream

Latest GRPH News From Around the Web

Below are the latest news stories about GRAPHITE BIO INC that investors may wish to consider to help them evaluate GRPH as an investment opportunity.

Graphite Bio in the red after downgrade by BofA Securities (NASDAQ:GRPH)

Graphite Bio (GRPH) was down around -9% on Wednesday after BofA Securities downgraded the stock to Neutral from Buy, with a price target of $3 (down from $7).BofA Securities analysts…

Seeking Alpha | January 18, 2023

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | January 10, 2023

Looking Into Graphite Bio''s Recent Short Interest

Graphite Bio''s (NASDAQ: GRPH ) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 1.25 million shares sold short , which is 5.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on

Benzinga | January 9, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

William White on InvestorPlace | January 6, 2023

Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study

Graphite Bio Inc (NASDAQ: GRPH ) voluntarily paused the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) following a serious adverse event in the first patient dosed with nula-cel. The company concluded that the event is likely related to the study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in … Full story available on

Benzinga | January 6, 2023

Read More 'GRPH' Stories Here

GRPH Price Returns

1-mo -35.97%
3-mo -45.96%
6-mo -38.41%
1-year -76.11%
3-year N/A
5-year N/A
YTD -41.57%
2022 -73.29%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5889 seconds.